Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in AML and High-Grade MDS
NCT00830518Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Feb 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Millennium Pharmaceuticals. Started Feb 2009; status: completed.
02
Drugs
alisertib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00830518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00830518.